I'm trying to forget that name :-) In platinum refractory ovarian cancer there is little else to hang a hat on. Perhaps a difference is there are more candidates to be the third drug in first line advanced NSCLC. It is a kind of Holy Grail. Stopping these trials will free up subjects.
I was listening very carefully on today's CC for Bratzler's answer regarding whether the '676 arm did worse than the control arms. "No indication of that." That could mean the DSMB just didn't say. Certainly, with Telcyta, the 'active' arms did worse than SOC. Would the DSMB stop these PFE trials this early just because there was no difference? Any opinions on the likelihood some side effect or worsening survival in the 676 group was seen? TIA
Market Data 
Markets 
AI
